Amgen is trading 3.00% down at $400.68, as a same-day report linked weakness to rival-trial concerns. - The failed Phase 3 pelacarsen cardiovascular-outcomes trial was Novartis’; it raised concern about related Lp(a) drugs, including Amgen’s olpasiran. The report did not say Amgen’s drug failed. - Broader pressure may also contribute: major U.S. indexes were lower, while biotech fell 2.04%. - Recent analyst target increases do not point to an obvious negative Amgen-specific rating action.